Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases

Genetic engineering is about to take a new step. Brink Therapeutics, a young biotechnology company founded in 2024, intends to revolutionize genome publishing by developing a programmable recombination technology capable of inserting long DNA sequences without resorting to double-strand breaks. An innovation that could eventually replace CRISPR-Cas9 in some cases of use, especially in the case of ... The article Brink Therapeutics secures €3.5 m…

Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases

Learn about Brink Tx as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy. The post Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be use…